$ANRO

Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620328d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 13, 2026 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGRE

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Alto Neuroscience reported a net loss of $26.2 million for Q1 2026, an increase from $15.2 million in Q1 2025, but ended the quarter with $264.2 million in cash following a March PIPE financing. The company expects this funding to support operations through 2029, including a potential NDA submission for ALTO-207. Key business highlights include the initiation of a Phase 2b trial for ALTO-207, advancements with ALTO-101, and ongoing Phase 2b trials for ALTO-300 and ALTO-100 with projected topline readouts in 2027.

Alto Neuroscience Inc. (ANRO:NYSE) is shifting its focus to ALTO-207, a drug targeting treatment-resistant depression, after mixed results from its ALTO-101 trial for cognitive impairment associated with schizophrenia. Despite the ALTO-101 setback, the company is moving forward with ALTO-207, planning a Phase 2b clinical trial, and has garnered 'Buy' and 'Outperform' ratings from multiple analysts who see significant market potential in addressing mental health conditions. The global market for psychotropic medications is projected to reach US$30 billion by 2030, driven by increased prevalence of mood disorders and improved diagnostics.

Alto Neuroscience, Inc. is holding its 2026 annual meeting on May 12, 2026, where stockholders will vote on several key proposals, including the election of two Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor, and amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan. The proposed amendments aim to adjust the "evergreen" formulas in the equity plans to include pre-funded warrants in the calculation of annual share reserve increases, aligning with a recent securities purchase agreement. The Board recommends voting "FOR" all four proposals, emphasizing the importance of these changes for long-term equity flexibility and employee incentives.

Alto Neuroscience Inc (ANRO) is anticipated to report a loss of 52 cents per share, according to this earnings preview. The article, sourced from Reuters, provides a brief outlook on the company's upcoming financial results.

Several Wall Street analysts have initiated coverage on companies like VSE Corp and Alto Neuroscience with optimistic Buy or Outperform ratings and specific price targets. Notably, BTIG analyst Thomas Shrader raised Alto Neuroscience's price target to $28 from $27, maintaining a Buy rating due to its precision psychiatry approach. The article also provides a company overview for Alto Neuroscience, highlighting its clinical-stage pipeline targeting various mental health conditions.

Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE). The investigations concern alleged breaches of fiduciary duty by the companies' officers and directors. Shareholders who held shares continuously prior to specific dates may have standing to seek corporate governance reforms and other remedies.

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.